PTK2 and prostate carcinoma: To date, most evidence suggests that FAK overexpression and FAK phosphorylation are markers for invasive and metastatic tumors, including Gastric cancer, colon cancer, thyroid cancer, ovarian cancer, prostate cancer, oral cancer [40–45].